- Home
- NJR vs TFX Comparison
NJR vs TFX Comparison
Compare NJR & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NJR | TFX |
|---|---|---|
| Founded | 1922 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NJR | TFX |
|---|---|---|
| Price | $46.37 | $122.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 10 |
| Target Price | $52.17 | ★ $139.88 |
| AVG Volume (30 Days) | 665.0K | ★ 767.4K |
| Earning Date | 02-02-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.10% | 1.12% |
| EPS Growth | ★ 14.04 | N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | $2,036,412,000.00 | ★ $3,189,988,000.00 |
| Revenue This Year | $9.90 | $9.90 |
| Revenue Next Year | $4.69 | $10.51 |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | ★ 13.35 | 5.42 |
| 52 Week Low | $43.46 | $102.58 |
| 52 Week High | $50.77 | $185.94 |
Technical Indicators
Market Signals| Indicator | NJR | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 52.75 |
| Support Level | $44.51 | $123.66 |
| Resistance Level | $48.02 | $127.88 |
| Average True Range (ATR) | 0.80 | 3.89 |
| MACD | 0.12 | 0.36 |
| Stochastic Oscillator | 52.99 | 38.14 |
Price Performance
Historical ComparisonAbout NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.